Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Current Deferred Revenue (2024 - 2025)

Historic Current Deferred Revenue for Gossamer Bio (GOSS) over the last 2 years, with Q3 2025 value amounting to $24.0 million.

  • Gossamer Bio's Current Deferred Revenue rose 1806.96% to $24.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.0 million, marking a year-over-year increase of 1806.96%. This contributed to the annual value of $17.0 million for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Gossamer Bio's Current Deferred Revenue is $24.0 million, which was up 1806.96% from $23.5 million recorded in Q2 2025.
  • In the past 5 years, Gossamer Bio's Current Deferred Revenue registered a high of $24.0 million during Q3 2025, and its lowest value of $17.0 million during Q2 2024.